Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Long term data is presented for Medtronic's Endeavor DES

Medtronic : 23 May, 2007  (New Product)
Medtronic has presented long term data from the Endeavor clinical trial programme that reinforces the existing safety and efficacy profile of the Endeavor drug-eluting coronary stent.
Four year results from the 100 patient first-in-man Endeavor I trial and three year results from the nearly 1,200 patient Endeavor II trial demonstrate that Endeavor is associated with sustained safety, significant reductions in repeat procedures and no late Stent thrombosis in either trial using the pre-specified trial protocol definitions.

The Endeavor II study also showed that the Medtronic Driver bare metal Stent offers consistent and durable long-term clinical results.

The data was presented by Andreas Zeiher, MD, J W Goethe-University, Frankfurt, Germany, during the EuroPCR's late breaking clinical trial session.

The Endeavor Stent is approved in more than 100 countries worldwide and currently is under review by the US Food and Drug Administration.

FDA approval is anticipated in the second half of 2007.

The Endeavor I data continues to show long term results, with only one clinical event between years three and four, a non-cardiac death from cancer.

Target Lesion Revascularization (TLR) at four years was 3.1 percent and Target Vessel Revascularization (TVR) was 5.2 percent.

The Major Adverse Cardiac Event (MACE) rate, one of the trial's primary endpoints, was 7.2 percent, with no late Stent thrombosis events in this patient cohort.

Through three years of follow-up in the Endeavor II trial, the TLR rate was 7.3 percent, compared to 14.7 percent for the Driver bare metal control arm (p= less than 0.001), representing a 50 percent reduction in the need for repeat procedures.

Target Vessel Failure, the trial's primary endpoint, was 12.8 percent for Endeavor and 21.4 percent for Driver, a 40 percent reduction (p= less than 0.001).

Endeavor showed a MACE rate of 12.0 percent at three years, compared to 20.7 percent for Driver (p= less than 0.001), while the combined cardiac death/myocardial infarction (MI) rate for Endeavor was 4.5 percent and 6.7 percent for Driver (p=0.125).

When compared to Driver, Endeavor has fewer total deaths, fewer cardiac deaths and fewer MIs at three years.

'These are well conceived and well managed clinical trials'.

'The results are excellent and the clinical investigators have achieved a very admirable level of patient follow-up', said Jean Fajadet, MD, Clinique Pasteur Unite de Cardiologie Interventionnelle, Toulouse, France, and one of the principal investigators for the Endeavor II trial.

'The number of repeat procedures is low, there are few adverse cardiac events and the lack of late Stent thrombosis is truly extraordinary'.

Using pre-specified, protocol-defined data adjudicated by the Harvard Clinical Research Institute, there have been no instances of late or very late Stent thrombosis among more than 1,300 patients receiving the Endeavor stent.

Dr Zeiher also presented Endeavor data using the broader Academic Research Consortium (ARC) definitions of Stent thrombosis.

Under the definitions for definite and probable Stent thrombosis, Endeavor's cumulative rate in the Endeavor I-III trials is 0.5 percent at three years and the Driver bare metal Stent has a rate of 1.5 percent.

Additionally, composite analysis of myocardial infarction and cardiac mortality showed three year freedom from death or MI of 96.0 percent for Endeavor and 93.4 percent for the Driver bare metal stent.

'The body of data now available on Endeavor is significant and the results are impressive', said Scott Ward, senior vice president of the cardioVascular business at Medtronic.

'We have made several major presentations of Endeavor data during the last year, with consistent and predictable results.

'Using either the pre-specified protocol definition or the new ARC definitions, these data demonstrate that Endeavor is highly effective at preventing repeat procedures without an increased safety risk, and with a favourably low incidence of death and myocardial infarction'.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo